Thiophosphate (SPO 3 ) was recently shown to promote cysteine insertion at Sec (selenocysteine)-encoding UGA codons during selenoprotein synthesis. We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity. This effect could possibly be attenuated in cells expressing less reactive Sec-to-cysteinesubstituted TrxR1 variants, or pronounced in cells with higher levels of Sec-containing TrxR1. To test this, we supplemented cells with either SPO 3 or selenium and subsequently determined total as well as specific activities of cellular TrxR1, together with extent of drug-induced cell death. We found that cDDP became less cytotoxic after incubation of A549 or HCT116 cells with lower SPO 3 concentrations (100-300 μM), whereas higher SPO 3 (>300 μM) had pronounced direct cytotoxicity. NIH 3T3 cells showed low basal TrxR1 activity and high susceptibility to SPO 3 cytotoxicity, or to glutathione depletion. Supplementing NIH 3T3 cells with selenite, however, gave increased cellular TrxR1 activity with concomitantly decreased dependence on glutathione, whereas the susceptibility to cDDP increased. The results suggest molecular mechanisms by which the selenium status of cells can affect their glutathione dependence while modulating the cytotoxicity of drugs that target TrxR1.
Thiophosphate (SPO 3 ) was recently shown to promote cysteine insertion at Sec (selenocysteine)-encoding UGA codons during selenoprotein synthesis. We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity. This effect could possibly be attenuated in cells expressing less reactive Sec-to-cysteinesubstituted TrxR1 variants, or pronounced in cells with higher levels of Sec-containing TrxR1. To test this, we supplemented cells with either SPO 3 or selenium and subsequently determined total as well as specific activities of cellular TrxR1, together with extent of drug-induced cell death. We found that cDDP became less cytotoxic after incubation of A549 or HCT116 cells with lower SPO 3 concentrations (100-300 μM), whereas higher SPO 3 (>300 μM) had pronounced direct cytotoxicity. NIH 3T3 cells showed low basal TrxR1 activity and high susceptibility to SPO 3 cytotoxicity, or to glutathione depletion. Supplementing NIH 3T3 cells with selenite, however, gave increased cellular TrxR1 activity with concomitantly decreased dependence on glutathione, whereas the susceptibility to cDDP increased. The results suggest molecular mechanisms by which the selenium status of cells can affect their glutathione dependence while modulating the cytotoxicity of drugs that target TrxR1.
INTRODUCTION
The Trx (thioredoxin) system, i.e. Trx and TrxR (thioredoxin reductase) using NADPH, supports several Trx-dependent cellular enzyme pathways in antioxidant defence, redox regulation and deoxyribonucleotide synthesis [1] [2] [3] [4] . Mammalian TrxR1 has a Sec (selenocysteine) residue within a conserved C-terminal GCUG motif that is essential for its Trx-reducing activity [5] [6] [7] [8] . The highly accessible chemically reactive Sec-containing active site of reduced mammalian TrxR1 makes the enzyme extraordinarily susceptible to a broad range of electrophilic compounds, thereby acting as inhibitors. Many such compounds are also used in anticancer treatment, where TrxR1 inhibition may play a role for their efficacy [9] .
Previous findings of ours showed that removal of Sec in TrxR1 through C-terminal truncation, or compromising its Sec residue by reaction with electrophiles such as cDDP [cis-diamminedichloroplatinum(II) or cisplatin], may lead to formation of pro-oxidant cytotoxic forms of TrxR1, named SecTRAPs (selenium-compromised thioredoxin reductasederived apoptotic proteins) [10, 11] . SecTRAPs are not solely inhibited inert forms of TrxR1, but can induce rapid cell death in A549 or HeLa cells through a gain of function, triggering the formation of ROS (reactive oxygen species) [10, 11] . Because the production of SecTRAPs may occur through targeting of the Sec residue in TrxR1 by electrophilic drugs, we wondered whether such effects could become attenuated if less reactive Sec-to-cysteine variants of TrxR1 become expressed in cells or, conversely, more pronounced in cells with higher levels of Seccontaining TrxR1. This question becomes important in the context of previous findings by others showing that Sec-to-cysteine variants of TrxR1 can indeed be formed in vivo under conditions of selenium deficiency [12, 13] and also upon the incubation of cells with thiophosphate (SPO 3 ) [12] . SPO 3 is a sulfur-substituted analogue of orthophosphate, and has long been known as a cytotoxic compound [14] . SPO 3 can be incorporated into DNA or RNA and give irreversible histone thiosphosphorylation, which makes nuclear DNA susceptible to damage and this can explain much of the SPO 3 cytotoxicity [14, 15] . In addition, it was shown recently that SPO 3 may compete with selenophosphate as a substrate for SecS (Sec synthase), thereby using phosphoseryl-tRNA [Ser] Sec and SPO 3 to synthesize cysteinylated tRNA [Ser] Sec , instead of selenocysteinylated tRNA [Ser] Sec that is normally produced in cells at seleniumsufficient conditions and utilized in selenoprotein synthesis. Thus SPO 3 can trigger incorporation of a cysteine residue at the Sec-dedicated UGA codon in TrxR1-encoding mRNA during the synthesis of this selenoprotein [12] . Using NIH 3T3 cells grown in the presence of SPO 3 in the medium, up to 96 % of the expressed TrxR1 was found using MS to be Sec-to-cysteinesubstituted [12] . However, in that recent study discovering this novel effect of SPO 3 , no analyses were made to determine the resulting total cellular activities of TrxR1 and no study of the impact on cell growth or cytotoxicity of SPO 3 was performed. Since SPO 3 has been described as a cytotoxic compound and TrxR1 is an important normally Sec-dependent enzyme, we reasoned that such studies would be of interest. In the present study, we therefore used the same cell incubation method with SPO 3 to promote synthesis of Sec-to-cysteine-substituted TrxR as described in [12] or, alternatively, saturated the Sec content of the enzyme by supplementing the cell medium with (trace) amounts of selenite, whereupon we measured the resulting total cellular TrxR activities. We also studied effects on cell proliferation and viability as well as analysed whether SPO 3 treatment might modulate the cytotoxicity of cDDP or glutathione depletion. The results give further insights into molecular mechanisms by which the dependence of cells on GSH, the total cellular activity of TrxR and its susceptibility to cDDP may all be modulated by the cellular selenium status and Sec-to-cysteine substitutions of TrxR1.
EXPERIMENTAL

Materials
Recombinant rat wild-type TrxR1 (24-28 units/mg) and the U498C mutant TrxR1 were produced as described in [16, 17] . Human wild-type Trx1 was generously provided by Professor Arne Holmgren (Karolinska Institutet). Polyclonal goat anti-TrxR1 primary antibody A-20 came from Santa Cruz Biotechnology. Rabbit polyclonal anti-(mouse TrxR1) serum was a gift from Dr Gary Merrill (Oregon State University, Corvalis, OR, U.S.A.). cDDP (Platinol ® ) was purchased from Bristol-Myers Squibb Pharmaceuticals. All other chemicals or reagents were obtained from Sigma-Aldrich unless stated otherwise.
Cell cultures
The human A549 (lung carcinoma) cell line was purchased from the A.T.C.C. (Manassas, VA, U.S.A.) and the HCT116 (colon carcinoma) cell line was kindly provided by Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, U.S.A.). Immortalized mouse NIH 3T3 fibroblasts were kindly provided by Professor Ulf Eriksson (Karolinska Institutet). All cells were cultured in DMEM (Dulbecco's modified Eagle's medium) with 4.5 g/l glucose content (Invitrogen) supplemented with 10 % (v/v) FBS (fetal bovine serum) (yielding an approximately 15-20 nM final concentration of selenium), 2 mM glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin (all from PAA Laboratories). Cells were grown in humidified air containing 5 % CO 2 at 37
• C and kept in a logarithmic growth phase for all experiments. SPO 3 was added as described in the text. The medium was not supplemented with any additional selenium source unless explicitly stated.
Western blot analyses
A total of 8 × 10 4 A549 cells, 15 × 10 4 HCT116 cells or 14 × 10 4 NIH 3T3 cells were seeded approximately 24 h before treatment. After incubation with SPO 3 or selenite at the indicated concentrations for 2 days (approximately 48 h), the cells were harvested and lysed, and the clarified supernatants were used for either analysis of TrxR enzymatic activities or Western blots. Total protein concentrations were determined with a Bradford reagent kit (Bio-Rad Laboratories). Polyclonal goat anti-TrxR1 primary antibody A-20 was used for A549 and HCT116 cells while a rabbit polyclonal anti-(mouse TrxR1) primary serum was used for NIH 3T3 cells. The SuperSignal West Pico kit (Thermo Fisher Scientific) was used according to the manufacturer's instructions, and the signals were detected using a Bio-Rad ChemiDoc XRS scanner and Quantity One ® software, version 4.6.7. The intensities of the TrxR bands were quantified by densitometric scanning using Gel-Pro Analyzer version 4.0.
TrxR activity assays with cell lysates
Cellular TrxR activity was determined using an adaptation of the Trx-dependent end-point insulin reduction assay for microwell plates, as described previously [18] .
Cell proliferation assays
A total of 2 × 10 3 cells/well for the 2-day treatment, 1.5 × 10 3 cells/well for the 4-day treatment, or 700 A549 cells/well and 500 HCT116 cells/well for the 5-day treatment were seeded on to 96-well microtitre plates approximately 24 h before exposure to SPO 3 or supplementation with selenite. SPO 3 or selenite with or without cDDP, DNCB (dinitrochlorobenzene) or BSO (buthionine sulfoximine) were included in the medium, at the concentrations indicated in the text, throughout the experiment. Cell proliferation was estimated using the CyQUANT Cell Proliferation Assay (Life Technologies) according to the manufacturer's instructions.
Cell viability assays using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide]
A total of 2 × 10 3 cells/well for the 2-day treatment was seeded for each cell line, whereas otherwise the culturing conditions were the same as those described above. For analysis, the cells were incubated with 0.5 mg/ml MTT at 37
• C for 4 h thereupon dissolved in DMSO. Absorbance was measured at 550 nm with cell-free samples as background.
LDH (lactate dehydrogenase) efflux assays
For determination of LDH efflux to the medium, 7 × 10 3 A549, 1 × 10 4 HCT116 or 1 × 10 4 NIH 3T3 cells for the 2-day treatments, 4 × 10 3 A549, 6 × 10 3 HCT116 or 6 × 10 3 NIH 3T3 cells for the 4-day treatments, and 2 × 10 3 A549 cells or 3 × 10 3 HCT116 cells for the 5-day treatments were seeded on to 96-well microtitre plates, whereas otherwise the culturing conditions were the same as those described above. For analysis, 100 μl of medium was incubated with 70 mM Tris/HCl (pH 7.2), 174 mM NaCl, 0.2 mM NADH and 1.4 mM pyruvate at room temperature (∼20
• C) in a final volume of 250 μl. The reverse LDH assay (reduction of pyruvate using NADH) was performed by monitoring the decrease in absorbance at 340 nm, recorded automatically at 30 s intervals over a 5 min period. LDH activity was determined from the slope of the absorbance curve and cellfree medium was used as background.
Statistics
Results are means + − S.E.M. Statistical evaluation was performed with the Mann-Whitney test using GraphPad Prism software, version 5.0. Asterisks (*) denote statistically significant differences (P < 0.05).
RESULTS
Effects of SPO 3 or selenium supplementation on cellular TrxR1 levels and its specific activities
Using the A549, HCT116 and NIH 3T3 cell lines, we found that supplementation of the medium with 100 nM selenite saturated their maximal cellular activities of TrxR1. We therefore used this selenite supplementation as baseline and subsequently lowered it in dilutions down to a complete lack of selenium supplementation, other than that resulting from 10 % (v/v) FBS. Additional supplementation with SPO 3 was subsequently used to further promote Sec-to-cysteine substitutions in TrxR1. The two human cancer cell lines A549 and HCT116 had higher maximal TrxR activities than found in the mouse NIH 3T3 fibroblasts ( Figure 1A , left-hand panel), consistent with the fact that many tumour cells have high TrxR1 expression levels [13] [14] [15] . However, the three cell lines showed different profiles in their changes in cellular TrxR activities with decreasing selenite and increasing SPO 3 ( Figure 1A ). A549 cells, with by far the highest total cellular TrxR activity at selenium-sufficient levels, displayed a continuum of dose-dependent reduction in cellular TrxR activity with decreasing selenite and subsequently increasing SPO 3 . In contrast, higher concentrations of selenite as well as SPO 3 increased the total cellular TrxR activity in HCT116 cells. The cellular TrxR activity in NIH 3T3 cells, finally, was low compared with the two cancer cell lines and did not change upon treatment with SPO 3 , whereas incubation with trace amounts of selenite substantially increased the TrxR activity in these cells ( Figure 1A) . Estimating the cellular specific activity of TrxR from the ratio of its total activity ( Figure 1A ) over the TrxR1 band intensity ( Figures 1B and 1C) showed that this clearly declined after SPO 3 treatment with all three cell types ( Figure 1D ), in good agreement with a lower catalytic turnover by the Sec-tocysteine-substituted enzyme [5] [6] [7] [8] shown previously to be formed under these conditions [12] . However, compared with baseline, the estimated specific activity of TrxR was increased in A549 NIH 3T3 cells were incubated with (hatched bars) or without (white bars) a trace amount of selenium (75 nM selenite) for 2 days (approximately 48 h). Subsequently, BSO was added at the concentrations indicated and incubation was continued for another 2 days (approximately 48 h). Cell proliferation, cell viability and LDH activity released to the extracellular medium were measured as in Figure 2 . Results are means + − S.E.M. of at least triplicate samples. Significant (P < 0.05) differences between treatments with or without selenite are indicated with an asterisk (*). n.s., not significant (P > 0.05).
and NIH 3T3 cells upon selenite supplementation, whereas it decreased in HCT116 cells ( Figure 1D ).
Conducting these experiments, we also observed decreased growth rates in all three cell lines upon exposure to higher concentrations of SPO 3 , whereas supplementation with 10-100 nM selenite displayed no apparent toxicity. Because SPO 3 supplementation affected the TrxR activities and could also affect global thiol and redox status of the cells, we next studied the cytotoxicity of SPO 3 in relation to TrxR activities in the cells and their sensitivity to glutathione depletion. and D) , cell viability (B and E) and release of LDH activity to the medium (C and F) were measured as in Figure 2 . Results are means + − S.E.M. of triplicate samples. Significant (P < 0.05) differences between SPO 3 -treated samples and those without SPO 3 are indicated with an asterisk (*). n.s., not significant (P > 0.05).
Figure 5 Effects of a trace amount of selenium on cell death induced by cDDP or DNCB with NIH 3T3 cells
Cells were incubated with (hatched bars) or without (white bars) selenium (75 nM selenite) for 2 days (approximately 48 h) and subsequently incubation was continued for another 2 days (approximately 48 h) with addition of cDDP (A) or DNCB (B) at the concentrations indicated. Thereupon cell proliferation, cell viability and release of LDH activity to the medium were measured as in Figure 2 . Results are means + − S.E.M. of at least triplicate samples. Significant (P < 0.05) differences between treatments with or without selenium are indicated with an asterisk (*). n.s., not significant (P > 0.05).
SPO 3 supplementation or to GSH depletion with BSO (an efficient inhibitor of GSH synthesis, virtually emptying cellular GSH stores under the conditions used herein [18] 3 or GSH depletion, whereas NIH 3T3 cells, having low TrxR1 activity, were highly sensitive to SPO 3 toxicity. The NIH 3T3 cells also displayed almost complete dependence on GSH, as revealed by a strong cytotoxicity of BSO. These conclusions were drawn from results of three different assays for cell viability, including measurements of cell proliferation based on assessment of total DNA content (Figure 2A ), cellular MTT reduction ( Figure 2B ) and LDH leakage to medium ( Figure 2C ). Because selenium supplementation increased the cellular TrxR activity in NIH 3T3 cells (Figure 1 ), we next analysed whether supplementation with selenium to these cells would affect their sensitivity to GSH depletion by BSO. Indeed, using supplementation with 75 nM selenite, which increased the TrxR activity approximately 7-fold in these cells ( Figure 1A ), we found a marked protection of these cells towards BSO treatment (Figure 3 ).
Sec-to-cysteine variants of TrxR1 are more resistant to inhibition by cDDP or DNCB, and SPO 3 modulates cell death induced by cDDP or DNCB in A549 or HCT116 cells
We next studied whether SPO 3 treatment might modulate the toxicity of cDDP or DNCB, two electrophilic drugs that target the Sec residue in TrxR1, which, as discussed above, is replaced by cysteine upon SPO 3 treatment of cells. First we confirmed that pure Sec-to-cysteine variants of TrxR1 would indeed be more resistant to inhibition by either cDDP or DNCB, as compared with the Sec-containing enzyme, which we, as expected, found that they were (Supplementary Figure  S1 at http://www.BiochemJ.org/bj/447/bj4470167add.htm). We also found that SPO 3 did not inhibit TrxR1 directly in a pure enzyme system, and neither did its inclusion affect the direct inhibition of Sec-containing TrxR1 by either cDDP or DNCB (Supplementary Figure S2 at http://www.BiochemJ.org/ bj/447/bj4470167add.htm). Thus any potential effects of SPO 3 on TrxR1 in a cellular context should be derived from indirect effects of SPO 3 , including its capacity to promote cellular expression of Sec-to-cysteine-variant TrxR1 species.
In order to assess whether SPO 3 incubation may affect TrxR1 inhibitor-triggered cell death, we first cultivated A549 or HCT116 cells together with intermediate concentrations of SPO 3 with regards to cytotoxicity (Figure 2 ) that still provoked a significant reduction in the specific activity of cellular TrxR1 (Figure 1) . We subsequently exposed such cells to either cDDP or DNCB. Interestingly, although SPO 3 displayed some cytotoxicity on its own account, these concentrations of SPO 3 attenuated parts of the cytotoxicity triggered by cDDP, as seen with A549 and HCT116 cells (Figures 4A-4C ). It also slightly protected A549 cells, but not HCT116 cells, from DNCB cytotoxicity (Figures 4D-4F ). Taken together, these experiments suggested that SPO 3 can indeed modulate the cytotoxic effects of compounds targeting TrxR1, although the effects are somewhat blurred by its own cytotoxicity.
We could not perform the corresponding experiments using NIH 3T3 cells because these cells displayed high susceptibility to SPO 3 cytotoxicity on its own account (Figure 2) . However, because NIH 3T3 cells also had very low TrxR1 activity (Figure 1 ) we wondered whether selenium supplementation, increasing their TrxR1 levels (Figure 1) , would also modulate their sensitivity to either cDDP or DNCB, which was studied next.
Effects of selenium supplementation on cDDP or DNCB cytotoxicity with A549, HCT116 or NIH 3T3 cells
In analyses of cDDP cytotoxicity in a background of selenium supplementation (75 nM selenite), we found no major effects by the selenium on the cDDP cytotoxicity with either A549 or HCT116 cells compared with non-supplemented controls (Supplementary Figure S3 at http://www.BiochemJ.org/ bj/447/bj4470167add.htm). However, the NIH 3T3 cells clearly became more susceptible to cDDP cytotoxicity upon selenium supplementation, as demonstrated with the MTT reduction assay or higher LDH release, but not apparent in the cell proliferation assay ( Figure 5A ). Interestingly, all three cell lines also displayed signs of increased resistance to DNCB treatment upon supplementation with 75 nM selenite, with the most pronounced protection seen with 5 μM DNCB treatment of NIH 3T3 cells ( Figure 5B and Supplementary Figure S3) . These results collectively showed that selenium supplementation can sensitize cells to cDDP and help protect cells from DNCB.
DISCUSSION
In the present study, we found that the selenium status of cells may have pronounced effects on their GSH-dependence as well as the cytotoxicity of drugs targeting TrxR1, such as cDDP. We also found it interesting that the three cell lines analysed, having different basal levels of TrxR1 activities, displayed rather divergent results upon SPO 3 exposure with regard to their total cellular TrxR activities. In contrast with what has been reported [19] , we found that selenium supplementation elevated the cellular TrxR activity only to a small extent in HCT116 cells, compared with largely increased TrxR1 protein levels. Therefore these cells displayed a decrease upon selenium supplementation in the specific activity of TrxR1, the mechanisms of which are yet unclear, but could possibly relate to oxidatively inactivated species of TrxR1. However, taken together, our results clearly illustrate that effects of selenium supplementation to cells can yield divergent and cell-type-specific effects on TrxR activities. This may relate to differences between cell types in capacities of selenium uptake [20] and will probably also involve factors related to direct regulation of TrxR1 expression.
Complementary functions between the Trx system and GSHdependent redox pathways have been suggested by many studies. Although Trx and thereby also TrxR1 are key players in many important cellular systems [1] [2] [3] [4] 9, [21] [22] [23] [24] , it is clear that TrxR1 knockdown or depletion will not necessarily yield a grave phenotype, in terms of cell viability or proliferation [18, [25] [26] [27] [28] . One major reason for the mild effects of isolated TrxR1 depletion, at least under certain conditions, seems to be that GSH-dependent pathways may instead support the same cellular functions [18, [26] [27] [28] [29] [30] [31] . We were therefore not surprised to find that, with only a trace level of cellular TrxR activity under control conditions, the NIH 3T3 cells highly relied on the GSH system in the absence of selenium supplementation. It was therefore reasonable that NIH 3T3 cells were highly susceptible to GSH depletion, as found in the present study and also shown previously by others [32] . The fact that NIH 3T3 cells became virtually resistant to BSO-triggered GSH depletion when their TrxR activity had been increased using selenium supplementation again suggested that either the Trx system or GSH can sufficiently support normal proliferative cell growth. The same principle was shown recently in regenerating liver using a hepatocyte-specific Txnrd1-knockout mouse model, where only the simultaneous depletion of both GSH and TrxR1 gave a phenotype with diminished cell proliferation [33] . SPO 3 promotes the production of Sec-to-cysteine-variant species of TrxR (TrxR-GCCG, illustrating the C-terminal tetrapeptide motif of the enzyme with C for cysteine, encoded by a UGA codon, shown in red) instead of the wild-type selenoprotein (TrxR-GCUG, where U in orange is Sec), as shown by the plus sign in red, while also being rather cytotoxic on its own account. Functions of the endogenous Trx system, maintaining cell viability and cell proliferation, can potentially be sustained by both wild-type and Sec-to-cysteine-variant TrxR species, which are complementary to GSH supporting cell viability and proliferation through the GSH system (open arrows). Only the Sec-containing form of TrxR is susceptible to inhibition by cDDP and can mediate some of the cytotoxicity of cDDP, both through inhibition of Trx system functions (blue minus sign) and the formation of toxic SecTRAPs (blue plus sign). DNCB can deplete GSH as well as inhibit wild-type TrxR (green minus signs), with the results of the present study indicating that higher levels of either wild-type Sec-containing TrxR or the Sec-to-cysteine-variant TrxR species mainly contribute to resistance to DNCB cytotoxicity. BSO depletes GSH from cells (purple minus sign) and will thus give toxic effects mainly in cells that solely depend upon GSH and not upon TrxR for growth. However, cells having higher TrxR activities become rather resistant to BSO, which could be achieved by the supplementation with selenium that increases the cellular TrxR activity (orange plus sign). See the text for further details.
The protection of NIH 3T3 cells by selenium supplementation towards DNCB cytotoxicity may also be the result of a protection from GSH depletion, because DNCB, in addition to being a TrxR1 inhibitor [34] , is also a substrate of GSTs (glutathione transferases) and, as such, can lead to GSH depletion [35] . This suggests that TrxR1 in cells can be mainly protective towards the effects of GSH depletion by DNCB, rather than being a cellular target of DNCB, which is also in line with results of TrxR1 siRNA (small interfering RNA) knockdown experiments showing sensitization towards DNCB [18] .
Many studies have suggested that TrxR1 is a uniquely reactive selenoprotein, with key functions for cancer cell viability, and therefore serves as an attractive target for anticancer therapy [36] [37] [38] . It is therefore important knowledge that SPO 3 , in spite of its own apparent cytotoxicity, could attenuate cell death induced by cDDP. Trace amounts of selenite, conversely, exaggerated the cytotoxicity of cDDP in NIH 3T3 cells, in accordance with the increased TrxR activity and the notion that targeting of TrxR1 contributes to cDDP cytotoxicity. The findings in the present study thereby support further the idea that the Sec residue of TrxR1 is a prime target for TrxR1 inhibition by cDDP and that when derivatized with cDDP new forms of TrxR1, known as SecTRAPs, may be produced with direct cell-killing properties [10, 11] . As shown in the present study, Sec-to-cysteine variants of TrxR1 are, in pure form, resistant to inhibition by cDDP (Supplementary Figure S1) . The attenuation of cDDP cytotoxicity by SPO 3 could thus, at least in part, be due to diminished formation of SecTRAPs. These findings thus provide a molecular mechanism by which the selenium status of cancer cells might modulate the impact of anticancer drugs that involve targeting of the Sec residue in TrxR1 as part of their mechanisms of action. Figure 6 is a scheme summarizing these main interpretations of the present study. The standard Trx-dependent insulin reduction assay was employed in 96-well microtitre plates for analyses of cDDP or DNCB inhibition of recombinant wild-type or Sec-to-cysteinesubstituted TrxR1. Briefly, recombinant wild-type rat TrxR1 (300 nM) or its Sec-to-cysteine-substituted variant (3 μM) were pre-reduced by incubation with 250 μM NADPH in TE buffer (50 mM Tris/HCl containing 2 mM EDTA, pH 7.5) at room temperature for 5 min, whereupon the indicated concentrations of cDDP or DNCB were added and incubation was continued for 1 h. Subsequently, duplicate aliquots (10 μl each) were removed and added to microtitre plate wells containing 20 μM hTrx1, 160 μM insulin and 300 μM NADPH in TE buffer in a total volume of 200 μl. NADPH consumption at 30
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• C was then monitored as the decrease in absorbance at 340 nm using a VersaMax Pure preparations of recombinant wild-type (wt) TrxR1 (300 nM in A or 25 nM in B, dark grey bars) or its Sec-to-cysteine mutant (U498C; 3 μM in A or 3.2 μM in B, light grey bars) were pre-incubated with 250 μM NADPH with or without addition of the concentrations of cDPP or DNCB indicated for 60 min, whereupon TrxR1 activity was determined using either (A) Trx-dependent insulin reduction or (B) direct DTNB reduction. Activities of wild-type TrxR1 are given on the left-hand y-axis, whereas activities of the U498C variant are given on the right-hand y-axis. Results are means + − S.E.M. of duplicate samples.
reader (Molecular Devices). Enzyme activity was calculated from the NADPH molar absorption coefficient of 6200 M − 1 · cm − 1 .
DTNB reduction assays with pure TrxR preparations
In wells of a 96-well microtitre plate, 25 nM wild-type TrxR1 or the 3.2 μM Sec-to-cysteine variant was pre-reduced using 250 μM NADPH in TE buffer and subsequently incubated with the indicated concentrations of compounds at room temperature for 1 h, in a total volume of 40 μl. A reaction mixture resulting in a final concentration of 2.5 mM DTNB and 300 μM NADPH was subsequently added to a total volume of 200 μl and the enzymatic formation of TNB − (5-mercapto-2-nitrobenzoate) anions was determined by following the absorbance increase at 412 nm using a VersaMax microplate reader. The enzyme turnover was calculated from the molar absorption coefficient of 13600 M − 1 · cm − 1 for TNB − and considering that two TNB − are produced per NADPH. (A) Pure preparations of recombinant wild-type TrxR1 (300 nM) were pre-incubated with or without addition of 1 mM SPO 3 with or without 250 μM NADPH for 3 h, as indicated, whereupon TrxR1 activity was measured using either Trx-dependent insulin reduction (dark grey bars) or direct DTNB reduction (light grey bars). The Trx-reducing activities are given on the left-hand y-axis, whereas the DTNB-reducing activities are given on the right-hand y-axis. (B) Pure preparations of recombinant wild-type TrxR1 (300 nM) were pre-incubated with 250 μM NADPH and 100 μM cDDP or 50 μM DNCB, with or without 1 mM SPO 3 as indicated, for 60 min, whereupon TrxR1 activity was determined employing a Trx-dependent insulin reduction assay. Results are means + − S.E.M. of duplicate samples.
